Identification of Ribosomal Protein S4, Y-Linked 1 as a cyclosporin A plus corticosteroid resistance gene

Rui Chang, Lin Chen, Guannan Su, Liping Du, Yang Qin, Jing Xu, Handan Tan, Chunjiang Zhou, Qingfeng Cao, Gangxiang Yuan, Aize Kijlstra, Peizeng Yang*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Combination of corticosteroids (CS) with cyclosporin A (CsA) is widely used in the treatment of autoimmune diseases, autoinflammatory diseases and transplantation rejection. However, some patients fail to respond or develop resistance to the combination regimen. In Vogt-Koyanagi-Harada (VKH) disease model, we performed RNA sequencing (RNA-seq) based transcriptomics, isobaric tags for relative and absolute quantification (iTRAQ) based proteomics and assays in vitro to screen and validate potential resistant molecules. We found that a total of 1697 differentially expressed genes (DEGs) and 21 differentially expressed proteins (DEPs) in CD4(+) T cells between CsA & CS-resistant and -sensitive VKH patients. Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4(+) T cells from male VKH patients to CsA & CS. Importantly, we showed that chlorambucil (CLB) could reverse the resistance by RPS4Y1 suppression. Taken together, we identify RPS4Y1 as an important CsA & CS resistance gene in VKH disease. Researchers should consider validating the resistant effect of RPS4Y1 in other autoimmune diseases or organ transplantation.

Original languageEnglish
Article number102465
Number of pages11
JournalJournal of Autoimmunity
Volume112
DOIs
Publication statusPublished - Aug 2020

Keywords

  • Transcriptomics
  • Proteomics
  • CsA & CS resistance
  • RPS4Y1
  • CLB
  • VKH disease
  • KOYANAGI-HARADA-DISEASE
  • CD4(+) T-CELLS
  • CHLORAMBUCIL
  • EXPRESSION
  • MANAGEMENT
  • DIAGNOSIS
  • RECOMMENDATIONS
  • PATTERNS
  • OUTCOMES
  • THERAPY

Cite this